Greater than half of patients with diabetes and a history of metabolic surgery (51%) experienced remission of their diabetes even in the event that they didn’t achieve significant weight reduction after surgery, in keeping with a recent study presented here today on the American Society for Metabolic and Bariatric Surgery (ASMBS) 2023 Annual Scientific Meeting.

Researchers from Mayo Clinic in Rochester, University of California San Francisco in Fresno, and Stony Brook University Medical Center in Recent York performed a multicenter retrospective study of patients with diabetes who underwent gastric bypass between 2008-2017. Patient demographics and clinical data were collected annually for 14 years on a complete of 815 patients with a median BMI of 45.1. Patients were followed for seven years on average, which researchers say is the longest study of patients with diabetes after gastric bypass.

Researchers concluded that the metabolic surgery patients were more prone to achieve full remission if there was no insulin use prior to surgery, a lesser need for diabetes medications, a shorter duration of the disease, a lower HbA1c at baseline, and better weight reduction after surgery – diabetes remission rates were proportional to weight reduction after surgery.

This study shows that diabetes remission isn’t fully contingent on weight reduction after gastric bypass surgery. The hot button is to keep up close monitoring and efficient management of diabetes after surgery. Metabolic surgery isn’t a magic pill, but it surely offers perhaps the one likelihood for many individuals to rid themselves of diabetes and its associated complications once and for all.”

Omar Ghanem, MD, lead study writer, metabolic surgeon at Mayo Clinic in Rochester, MN

“Health professionals should take these aspects that play into remission into consideration when choosing patients for metabolic surgery and counseling them in regards to the potential health outcomes,” said Teresa LaMasters, MD, President, ASMBS, a bariatric surgeon and board-certified obesity medicine physician, who was not involved within the study. “There is no such thing as a other therapy that produce such results and patients and their doctors owe it to themselves to explore the choice to see if it’s right for them. Gastric bypass has been known to place diabetes into remission even before significant weight is lost.”

The ASMBS reports only about 1% of those that meet eligibility requirements get weight-loss surgery in any given yr. In 2020, the variety of bariatric procedures dropped to lower than 200,000, the bottom in 4 years, as a consequence of cancellations or deferrals through the height of the COVID-19 pandemic.

In response to the U.S. Centers for Disease Control and Prevention (CDC), obesity affects 42.4% of Americans. Studies show the disease can weaken or impair the body’s immune system and cause chronic inflammation and increase the chance of many other diseases and conditions including heart problems, stroke, type 2 diabetes, certain cancers, and COVID-19.

The Centers for Disease Control and Prevention (CDC) reports that 37.3 million people have diabetes or little greater than 11% of the US population. In 2018, a complete of 8.25 million hospital discharges were reported with diabetes — 1.87 million for major cardiovascular diseases, including: 440,000 for ischemic heart disease; 334,000 for stroke; 154,000 for a lower-extremity amputation; 226,000 for hyperglycemic crisis; and 60,000 for hypoglycemia. The CDC estimates the whole direct and indirect estimated costs of diagnosed diabetes in the USA in 2017 was $327 billion.

Source:

American Society for Metabolic and Bariatric Surgery